Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neuromyelitis optica.

Marcelo Matiello1, Anu Jacob, Dean M Wingerchuk

  • 1Department of Neurology, Mayo Clinic College of Medicine, Rochester, Minnesota 55905, USA.

Current Opinion in Neurology
|May 15, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunity Gone Viral: Subacute Cognitive Decline With Multifocal Brain Lesions in Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.

PloS one·2026
Same author

Should autologous HSCT be a first-line option in highly active MS? No.

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Identification of genetic risk loci associated with aquaporin 4-positive neuromyelitis optica spectrum disorder: a genome-wide association study.

The Lancet. Neurology·2026
Same author

Comparative Effectiveness of Disease-Modifying Treatments in Double Seronegative Neuromyelitis Optica Spectrum Disorder.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same author

Cerebrovascular Manifestations of Neurosarcoidosis - An Overview.

Vascular health and risk management·2026
Same journal

Movement disorders and Parkinson's disease: collaborative and interdisciplinary research to advance understanding of neural circuit dysfunction, pathophysiology, and care: new horizons in technology, neuroimaging, neurophysiology, and genetics toward personalized medicine.

Current opinion in neurology·2026
Same journal

Editorial introduction.

Current opinion in neurology·2026
Same journal

Multimodal mapping of balance dysfunction in Parkinson's disease: a consensus roadmap for research and intervention.

Current opinion in neurology·2026
Same journal

Tourette syndrome: brain neurophysiology, circuit dysfunction, and neuromodulation across invasive and noninvasive approaches.

Current opinion in neurology·2026
Same journal

Dystonia: from phenotypes to genetics and therapeutic advances.

Current opinion in neurology·2026
Same journal

What can we learn from eye movements in movement disorders and Parkinson's disease?

Current opinion in neurology·2026
See all related articles

Neuromyelitis optica immunoglobulin G (NMO-IgG) is a key biomarker distinguishing neuromyelitis optica from multiple sclerosis. Identifying aquaporin-4 as the target of NMO-IgG advances understanding and treatment of these CNS demyelinating diseases.

Area of Science:

  • Neuroimmunology
  • Central Nervous System Disorders
  • Demyelinating Diseases

Background:

  • Neuromyelitis optica is an idiopathic inflammatory demyelinating disease affecting the optic nerves and spinal cord.
  • Distinguishing neuromyelitis optica from multiple sclerosis is crucial for effective treatment.

Purpose of the Study:

  • Review recent advances in neuromyelitis optica research.
  • Focus on the neuromyelitis optica immunoglobulin G (NMO-IgG) biomarker.
  • Highlight the identification of aquaporin-4 as the molecular target of NMO-IgG.

Main Methods:

  • Indirect immunofluorescence for NMO-IgG detection.
  • Analysis of NMO-IgG presence and specificity in diverse populations.
  • Immunopathologic studies examining aquaporin-4 expression in lesions.

Related Experiment Videos

Main Results:

  • NMO-IgG presence confirms neuromyelitis optica diagnosis and broadens its recognized spectrum.
  • Aquaporin-4 identified as the molecular target of NMO-IgG.
  • Loss of aquaporin-4 immunostaining observed in early neuromyelitis optica lesions.
  • Rituximab shows potential efficacy in treatment-resistant cases.

Conclusions:

  • Neuromyelitis optica has distinct clinical, radiologic, and immunologic features compared to multiple sclerosis.
  • NMO-IgG is the first specific biomarker for a CNS demyelinating disease.
  • Understanding aquaporin-4's role in NMO-IgG pathogenesis may improve treatment strategies for idiopathic inflammatory demyelinating diseases.